TNSN93012A1 - Conception, clonage et expression d'anticorps monoclonaux humanises contre l'interleukine-5 humaine - Google Patents
Conception, clonage et expression d'anticorps monoclonaux humanises contre l'interleukine-5 humaineInfo
- Publication number
- TNSN93012A1 TNSN93012A1 TNTNSN93012A TNSN93012A TNSN93012A1 TN SN93012 A1 TNSN93012 A1 TN SN93012A1 TN TNSN93012 A TNTNSN93012 A TN TNSN93012A TN SN93012 A TNSN93012 A TN SN93012A TN SN93012 A1 TNSN93012 A1 TN SN93012A1
- Authority
- TN
- Tunisia
- Prior art keywords
- monoclonal antibodies
- humanized monoclonal
- human interleukin
- cloning
- expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
UN ANTICOPRS MONOCLONAL EST PREVU QUI SE LIE SPECIFIQUEMENT A L'INTERLEUKINE-5 HUMAINE. SONT EGALEMENT PREVUS UN HYDRODOME QUI PRODIT L'ANTICORPS MONOCLONAL ; DES ADN COMPLEMENTAIRES QUI CODENT LES REGIONS VARIABLES DES CHAINES LOURDE ET LEGERE D'UN L'ANTICORPS MONOCLONAL ET LEUR CDR ; LES ANTICORPS MONOCLONAUX HUMANISES ; ET LES COMPOSITIONS PHARMACEUTIAUES COMPRENANT L'ANTICORPS MONOCLONAL OU DES ANTICORPS ANTI- IDIOTYPIQUES DIRIGES CONTRE LUI, LES ANTICORPS MONOCLONAUX HUMANISES, LES FRAGMENTS DE LIAISON, LES COMPOSITIONS OU DES PROTEINES DE LIAISON A UNE SEULE CHAINE QUI SONT DERIVEES DE L'ANTICORPS ET UN SUPPORT PHYSIOLOGIQUEMENT ACCEPTABLE
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83284292A | 1992-02-06 | 1992-02-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN93012A1 true TNSN93012A1 (fr) | 1994-03-17 |
Family
ID=25262763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNTNSN93012A TNSN93012A1 (fr) | 1992-02-06 | 1993-02-05 | Conception, clonage et expression d'anticorps monoclonaux humanises contre l'interleukine-5 humaine |
Country Status (21)
Country | Link |
---|---|
US (1) | US6451982B1 (fr) |
EP (1) | EP0625201A1 (fr) |
JP (2) | JPH07505767A (fr) |
KR (2) | KR0150060B1 (fr) |
CN (1) | CN1077991A (fr) |
AR (1) | AR248044A1 (fr) |
AU (1) | AU683836B2 (fr) |
CA (1) | CA2129445A1 (fr) |
CZ (1) | CZ291039B6 (fr) |
FI (1) | FI943635A0 (fr) |
HU (1) | HUT67943A (fr) |
IL (1) | IL104620A (fr) |
NO (1) | NO942912L (fr) |
NZ (1) | NZ249633A (fr) |
PL (1) | PL176393B1 (fr) |
RU (1) | RU94045919A (fr) |
SG (1) | SG49597A1 (fr) |
SK (1) | SK280610B6 (fr) |
TN (1) | TNSN93012A1 (fr) |
WO (1) | WO1993016184A1 (fr) |
ZA (1) | ZA93779B (fr) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993016184A1 (fr) | 1992-02-06 | 1993-08-19 | Schering Corporation | Fabrication, clonage et expression d'anticorps monoclonaux humanises diriges contre l'interleukine-5 humaine |
USRE39548E1 (en) * | 1994-06-17 | 2007-04-03 | Celltech R&D Limited | Interleukin-5 specific recombinant antibodies |
GB9412230D0 (en) | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
US6056957A (en) * | 1994-08-04 | 2000-05-02 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-5 |
AU708951B2 (en) * | 1994-12-23 | 1999-08-19 | Smithkline Beecham Corporation | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
US5693323A (en) * | 1994-12-23 | 1997-12-02 | Smithkline Beecham Corporation | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
US7399837B2 (en) | 1995-12-22 | 2008-07-15 | Smithkline Beecham Corporation | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
US5683983A (en) * | 1995-06-07 | 1997-11-04 | Glaxo Group Limited | Peptides and compounds that bind to the IL-5 receptor |
US5668110A (en) * | 1995-06-07 | 1997-09-16 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
US5677280A (en) * | 1995-06-07 | 1997-10-14 | Glaxo Group Limited | Peptides and compounds that bind to the IL-5 receptor |
US5654276A (en) * | 1995-06-07 | 1997-08-05 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
DE69633973T2 (de) | 1995-09-11 | 2005-12-22 | Kyowa Hakko Kogyo Co., Ltd. | Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor |
US6228360B1 (en) * | 1998-08-19 | 2001-05-08 | Ajinomoto Co., Inc. | Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody |
US7109299B1 (en) | 1999-12-16 | 2006-09-19 | Affymax, Inc. | Peptides and compounds that bind to the IL-5 receptor |
KR100453877B1 (ko) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
CA2479927C (fr) | 2002-03-29 | 2013-03-12 | Schering Corporation | Anticorps monoclonaux humains anti-interleukine-5 et procedes et compositions les contenant |
US7927840B2 (en) * | 2006-09-11 | 2011-04-19 | Gen Probe Incorporated | Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region |
CA2957200C (fr) * | 2002-10-16 | 2020-05-26 | Gen-Probe Incorporated | Compositions et methodes de detection du virus du nil occidental |
PL211180B1 (pl) | 2002-12-17 | 2012-04-30 | Merck Patent Gmbh | Białko fuzyjne typu przeciwciało-IL2, wektor zawierający sekwencję kwasów nukleinowych kodujących takie białko, kompozycja farmaceutyczna zawierająca takie białko fuzyjne oraz jego zastosowania do wytwarzania leków |
ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
JP4954709B2 (ja) | 2004-10-28 | 2012-06-20 | 協和発酵キリン株式会社 | 子宮内膜症治療剤 |
EP1835929B8 (fr) | 2005-01-06 | 2016-07-27 | Novo Nordisk A/S | Procédés et traitements combinés anti-kir |
AU2006226733C9 (en) | 2005-03-23 | 2019-03-14 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
WO2008134721A1 (fr) | 2007-04-30 | 2008-11-06 | Smithkline Beecham Corporation | Méthodes pour administrer des anticorps anti-il-5 |
CA2719786A1 (fr) | 2008-03-28 | 2009-10-01 | Glaxosmithkline Llc | Procedes de traitement |
AU2009306708A1 (en) * | 2008-10-23 | 2010-04-29 | F. Hoffmann-La Roche Ag | Determination of immunoglobulin encoding nucleid acid |
KR101941514B1 (ko) | 2010-12-22 | 2019-01-23 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 개선된 반감기를 가지는 변형된 항체 |
US20150010544A1 (en) | 2011-12-16 | 2015-01-08 | Synthon Biopharmaceuticals B.V. | Compounds and methods for treating inflammatory diseases |
US9677018B2 (en) | 2013-01-09 | 2017-06-13 | Thyssenkrupp Industrial Solutions Ag | Process for the production of synthesis gas from hard coal |
WO2016040007A1 (fr) | 2014-09-08 | 2016-03-17 | Cephalon, Inc. | Utilisation de reslizumab pour traiter un asthme éosinophilique modéré à sévère |
AU2016311385C1 (en) | 2015-08-24 | 2019-08-22 | Glaxosmithkline Intellectual Property (No. 2) Limited | Biopharmaceutical compositions |
JP7295038B2 (ja) | 2017-06-06 | 2023-06-20 | グラクソスミスクライン エルエルシー | 小児患者のための生物薬剤組成物及び方法 |
JP2019026625A (ja) * | 2017-08-03 | 2019-02-21 | 日本全薬工業株式会社 | 抗イヌcd20モノクローナル抗体 |
US11224653B2 (en) | 2017-08-24 | 2022-01-18 | Cephalon, Inc. | Treatment strategy for non-responders to 100MG subcutaneous mepolizumab |
EP3689906A4 (fr) * | 2017-09-29 | 2021-04-07 | Jiangsu Hengrui Medicine Co., Ltd. | Anticorps il-5, son fragment liant l'antigène et son utilisation médicale |
CN109942706A (zh) * | 2017-12-21 | 2019-06-28 | 三生国健药业(上海)股份有限公司 | 结合人il-5的单克隆抗体、其制备方法和用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5096704A (en) | 1988-11-03 | 1992-03-17 | Schering Corporation | Method of treating eosinophilia |
AU633034B2 (en) * | 1988-11-03 | 1993-01-21 | Schering Corporation | Method of preventing or reducing eosinophilia |
WO1990005144A1 (fr) | 1988-11-11 | 1990-05-17 | Medical Research Council | Ligands a domaine unique, recepteurs comprenant lesdits ligands, procedes pour leur production, et emploi desdits ligands et recepteurs |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
CA2041271A1 (fr) * | 1990-04-30 | 1991-10-31 | Bradford A. Jameson | Peptides analogues aux proteines de la grande famille des immunoglobines |
WO1993016184A1 (fr) | 1992-02-06 | 1993-08-19 | Schering Corporation | Fabrication, clonage et expression d'anticorps monoclonaux humanises diriges contre l'interleukine-5 humaine |
-
1993
- 1993-02-04 WO PCT/US1993/000759 patent/WO1993016184A1/fr not_active Application Discontinuation
- 1993-02-04 ZA ZA93779A patent/ZA93779B/xx unknown
- 1993-02-04 EP EP93905764A patent/EP0625201A1/fr not_active Withdrawn
- 1993-02-04 SK SK918-94A patent/SK280610B6/sk unknown
- 1993-02-04 CA CA002129445A patent/CA2129445A1/fr not_active Abandoned
- 1993-02-04 HU HU9402293A patent/HUT67943A/hu unknown
- 1993-02-04 CZ CZ19941910A patent/CZ291039B6/cs not_active IP Right Cessation
- 1993-02-04 AR AR93324239A patent/AR248044A1/es active
- 1993-02-04 SG SG1996000571A patent/SG49597A1/en unknown
- 1993-02-04 KR KR1019940702711A patent/KR0150060B1/ko active
- 1993-02-04 JP JP5514104A patent/JPH07505767A/ja active Pending
- 1993-02-04 IL IL10462093A patent/IL104620A/xx not_active IP Right Cessation
- 1993-02-04 NZ NZ249633A patent/NZ249633A/en unknown
- 1993-02-04 RU RU94045919/13A patent/RU94045919A/ru unknown
- 1993-02-04 PL PL93304715A patent/PL176393B1/pl unknown
- 1993-02-04 AU AU36560/93A patent/AU683836B2/en not_active Ceased
- 1993-02-05 CN CN93102685A patent/CN1077991A/zh active Pending
- 1993-02-05 TN TNTNSN93012A patent/TNSN93012A1/fr unknown
-
1994
- 1994-08-05 NO NO942912A patent/NO942912L/no not_active Application Discontinuation
- 1994-08-05 FI FI943635A patent/FI943635A0/fi unknown
- 1994-08-06 KR KR1019940702711A patent/KR950700413A/ko not_active IP Right Cessation
-
1999
- 1999-11-11 JP JP11321698A patent/JP2000210097A/ja active Pending
-
2000
- 2000-03-28 US US09/537,911 patent/US6451982B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
RU94045919A (ru) | 1996-11-10 |
SG49597A1 (en) | 1998-06-15 |
NO942912L (no) | 1994-10-06 |
SK280610B6 (sk) | 2000-05-16 |
NO942912D0 (fr) | 1994-08-05 |
US6451982B1 (en) | 2002-09-17 |
JPH07505767A (ja) | 1995-06-29 |
WO1993016184A1 (fr) | 1993-08-19 |
PL176393B1 (pl) | 1999-05-31 |
CZ191094A3 (en) | 1994-12-15 |
HU9402293D0 (en) | 1994-10-28 |
KR950700413A (ko) | 1995-01-16 |
FI943635A (fi) | 1994-08-05 |
IL104620A0 (en) | 1993-06-10 |
AR248044A1 (es) | 1995-05-31 |
IL104620A (en) | 2000-02-29 |
KR0150060B1 (ko) | 1998-08-17 |
EP0625201A1 (fr) | 1994-11-23 |
AU683836B2 (en) | 1997-11-27 |
ZA93779B (en) | 1993-08-05 |
HUT67943A (en) | 1995-05-29 |
FI943635A0 (fi) | 1994-08-05 |
AU3656093A (en) | 1993-09-03 |
NZ249633A (en) | 1995-12-21 |
JP2000210097A (ja) | 2000-08-02 |
CN1077991A (zh) | 1993-11-03 |
SK91894A3 (en) | 1995-02-08 |
CA2129445A1 (fr) | 1993-08-07 |
CZ291039B6 (cs) | 2002-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN93012A1 (fr) | Conception, clonage et expression d'anticorps monoclonaux humanises contre l'interleukine-5 humaine | |
BG109311A (en) | PHARMACEUTICAL COMPOSITION, INCLUDING HUMAN ANTIBODIES CONNECTING HUMAN TNFAL, AND HIS APPLICATION | |
DE69636450D1 (de) | PEPTIDE UND PEPTIDOMIMETIKA MIT STRUKTURELLER ÄHNLICHKEIT MIT p53 UND DIE DIE p53-FUNKTION AKTIVIEREN | |
MY109957A (en) | Improved antibodies to plasmodium falciparum | |
DK0724456T3 (da) | CD40-Antistoffer | |
MX9704897A (es) | Secuencias del anticuerpo anti-idiotipo monoclonal recombinante 3h1 relacionadas con el antigeno carcinoembrionico humano. | |
PT941121E (pt) | Preparados farmaceuticos liofilizados, estaveis, de anticorpos monoclonais ou policlonais | |
DE68925226D1 (de) | Monoklonale Antikörper | |
NZ508381A (en) | Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5) | |
ES2187946T3 (es) | Uso de interleucina-15. | |
GR3020610T3 (en) | Monoclonal antibodies against tumor associated antigen, their preparation and use | |
DE69233125D1 (de) | Inhibitorische immunglobulin-polypeptide gegen den pdgf beta-rezeptor | |
DK0802924T3 (da) | Lægemiddel til forlænget immunsuppression og eliminering af tumorceller | |
DE3751319D1 (de) | VERWENDUNG UND ZUSAMMENSETZUNG ZUR VERBESSERUNG DES "TARGETING" VON ANTIKöRPERN, ANTIKöRPERTEILEN, SOWIE KONJUGATE DERSELBEN. | |
EP0770624A3 (fr) | Peptide pouvant induire une réponse immune contre le cancer de l'estomac et agent contenant ce peptide pour la prévention ou le traitement du cancer de l'estomac | |
DE69333952D1 (de) | Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen. | |
DK0817650T3 (da) | Syntetiske peptider og farmaceutiske sammensætninger, der omfatter disse, til behandling af systemisk lupus erythematosus | |
FI20095269A (fi) | Lymfosyyttien sitoutumiseen vaikuttava ihmisen endoteelisolun molekyyli | |
TR199801769T2 (xx) | D���k reg�lasyona diren�li C3 d�n��t�r�c�ler. | |
CA2107329A1 (fr) | Anticorps recombinants anti-virus de l'immunodeficience humaine | |
HUP0003029A2 (hu) | Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk | |
GB2333295A (en) | Modified protein G and fragments thereof |